ATE318146T1 - Verfahren zur aufkonzentrierung von antikörperlösungen - Google Patents
Verfahren zur aufkonzentrierung von antikörperlösungenInfo
- Publication number
- ATE318146T1 ATE318146T1 AT97923962T AT97923962T ATE318146T1 AT E318146 T1 ATE318146 T1 AT E318146T1 AT 97923962 T AT97923962 T AT 97923962T AT 97923962 T AT97923962 T AT 97923962T AT E318146 T1 ATE318146 T1 AT E318146T1
- Authority
- AT
- Austria
- Prior art keywords
- antibodies solutions
- concentrating
- concentrating antibodies
- solutions
- antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9610992.1A GB9610992D0 (en) | 1996-05-24 | 1996-05-24 | Concentrated antibody preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE318146T1 true ATE318146T1 (de) | 2006-03-15 |
Family
ID=10794316
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT97923962T ATE318146T1 (de) | 1996-05-24 | 1997-05-22 | Verfahren zur aufkonzentrierung von antikörperlösungen |
Country Status (28)
Country | Link |
---|---|
US (1) | US6252055B1 (de) |
EP (1) | EP0907378B1 (de) |
JP (1) | JP3338060B2 (de) |
KR (1) | KR20000015935A (de) |
CN (1) | CN1219882A (de) |
AP (1) | AP9801392A0 (de) |
AR (1) | AR007249A1 (de) |
AT (1) | ATE318146T1 (de) |
AU (1) | AU731950B2 (de) |
BR (1) | BR9709267A (de) |
CA (1) | CA2254983A1 (de) |
CO (1) | CO4850562A1 (de) |
CZ (1) | CZ382498A3 (de) |
DE (1) | DE69735295T2 (de) |
EA (1) | EA001860B1 (de) |
ES (1) | ES2258277T3 (de) |
GB (1) | GB9610992D0 (de) |
ID (1) | ID16966A (de) |
IL (1) | IL126940A0 (de) |
IS (1) | IS4892A (de) |
NO (1) | NO985464L (de) |
NZ (1) | NZ332625A (de) |
PE (1) | PE69098A1 (de) |
PL (1) | PL330111A1 (de) |
TR (1) | TR199802423T2 (de) |
WO (1) | WO1997045140A1 (de) |
YU (1) | YU53098A (de) |
ZA (1) | ZA974486B (de) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
EP1174148A4 (de) * | 1999-04-28 | 2005-05-04 | Yamanouchi Pharma Co Ltd | Parenterale medizinische zusammensetzungen enthaltend fragmente humanisierter monoklonaler antikörper und methode zur stabilisierung derselben |
JP4812228B2 (ja) * | 2000-08-10 | 2011-11-09 | 中外製薬株式会社 | 抗体含有溶液の凝集物生成または白濁抑制方法 |
US8703126B2 (en) | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
ES2332402T5 (es) * | 2000-10-12 | 2018-05-14 | Genentech, Inc. | Formulaciones de proteína concentradas de viscosidad reducida |
US6365395B1 (en) * | 2000-11-03 | 2002-04-02 | Millipore Corporation | Process for removing protein aggregates and virus from a protein solution |
US20020141970A1 (en) * | 2001-03-05 | 2002-10-03 | Pettit Dean K. | Stable aqueous solutions of granulocyte macrophage colony-stimulating factor |
AU2006202688B2 (en) * | 2001-05-31 | 2009-01-22 | Genentech, Inc. | Stable liquid formulations of antibodies |
GB0113179D0 (en) | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
CA2868614A1 (en) * | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
CA2454587C (en) | 2001-07-25 | 2012-11-13 | Protein Design Labs, Inc. | Stable lyophilized pharmaceutical formulation of igg antibodies |
US20080026068A1 (en) * | 2001-08-16 | 2008-01-31 | Baxter Healthcare S.A. | Pulmonary delivery of spherical insulin microparticles |
AU2002342151B2 (en) * | 2001-10-26 | 2007-07-19 | Immuno-Rx, Inc. | Immunotherapy for reversing immune suppression |
JP5290489B2 (ja) * | 2001-11-08 | 2013-09-18 | アッヴィ・バイオセラピューティクス・インコーポレイテッド | Igg抗体の安定な液体医薬製剤 |
WO2003066669A2 (en) * | 2002-02-04 | 2003-08-14 | Millipore Corporation | Process for removing protein aggregates and virus from a protein solution |
EP2311489A3 (de) | 2002-02-14 | 2013-08-21 | Chugai Seiyaku Kabushiki Kaisha | Formularierung Antikörper-enthaltender Lösungen die einen Zucker als Stabilisator beinhalten. |
US20160279239A1 (en) | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
US7132100B2 (en) * | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
EP1551875A4 (de) * | 2002-06-21 | 2006-06-28 | Biogen Idec Inc | Gepufferte formulierungen zur konzentrierung von antikörpern und verfahren zu deren anwendung |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
MY150740A (en) | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
EP3777880A1 (de) | 2003-02-10 | 2021-02-17 | Biogen MA Inc. | Immunglobulinformulierung und verfahren zur herstellung davon |
AU2012202845B2 (en) * | 2003-02-10 | 2014-09-04 | Biogen Ma Inc. | Immunoglobulin formulation and method of preparation thereof |
US20050158303A1 (en) * | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
CN1798575A (zh) | 2003-04-04 | 2006-07-05 | 健泰科生物技术公司 | 高浓度抗体和蛋白制剂 |
US8080642B2 (en) | 2003-05-16 | 2011-12-20 | Vical Incorporated | Severe acute respiratory syndrome DNA compositions and methods of use |
EP1532983A1 (de) * | 2003-11-18 | 2005-05-25 | ZLB Bioplasma AG | Immunoglobulinpräparationen mit erhöhter Stabilität |
CN1953768B (zh) * | 2004-02-12 | 2010-10-13 | 默克专利有限公司 | 抗-egfr抗体的高浓缩液体制剂 |
WO2005086698A2 (en) * | 2004-03-04 | 2005-09-22 | Mayo Foundation For Medical Education And Research | Methods for altering t cell diversity |
US8728525B2 (en) | 2004-05-12 | 2014-05-20 | Baxter International Inc. | Protein microspheres retaining pharmacokinetic and pharmacodynamic properties |
JP2007537288A (ja) | 2004-05-12 | 2007-12-20 | バクスター インターナショナル インコーポレイテッド | オリゴヌクレオチド含有マイクロスフェア、1型糖尿病を処置する医薬の製造のための、その使用 |
JP5634009B2 (ja) | 2004-05-12 | 2014-12-03 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | タンパク質を含み、そして高濃度のタンパク質で注射性能を示すミクロスフェア |
MXPA06012990A (es) | 2004-05-12 | 2007-02-12 | Baxter Int | Microesferas de acidos nucleicos, produccion y suministro de las mismas. |
US20060051347A1 (en) * | 2004-09-09 | 2006-03-09 | Winter Charles M | Process for concentration of antibodies and therapeutic products thereof |
JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
US7811572B2 (en) | 2005-08-24 | 2010-10-12 | Immunogen, Inc. | Process for preparing purified drug conjugates |
US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
EP1871806A2 (de) | 2005-03-08 | 2008-01-02 | Pharmacia & Upjohn Company LLC | Antikörperzusammensetzungen gegen madcam |
US20080311078A1 (en) | 2005-06-14 | 2008-12-18 | Gokarn Yatin R | Self-Buffering Protein Formulations |
AU2006296399B2 (en) * | 2005-09-30 | 2011-01-20 | Medimmune Limited | Interleukin-13 antibody composition |
AR059066A1 (es) | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
KR20140071452A (ko) | 2006-04-05 | 2014-06-11 | 애브비 바이오테크놀로지 리미티드 | 항체 정제 |
EP2647712A3 (de) | 2006-08-04 | 2013-11-20 | Baxter International Inc | Zusammensetzung auf Mikrokügelchenbasis zur Vorbeugung und/oder Umkehrung einer Neuerkrankung an autoimmun bedingter Diabetes |
EP2527364A1 (de) | 2007-03-29 | 2012-11-28 | Abbott Laboratories | Kristalline Antikörper gegen menschliches IL-12 |
WO2008131129A2 (en) | 2007-04-17 | 2008-10-30 | Baxter International Inc. | Nucleic acid microparticles for pulmonary delivery |
EP2173163A4 (de) * | 2007-07-06 | 2010-12-08 | Glaxosmithkline Llc | Antikörperformulierungen |
WO2009010269A1 (en) * | 2007-07-17 | 2009-01-22 | F.Hoffmann-La Roche Ag | Variable tangential flow filtration |
JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
WO2009068282A1 (en) * | 2007-11-29 | 2009-06-04 | F. Hoffmann-La Roche Ag | Immunoglobulin aggregates |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
WO2009083225A2 (en) * | 2007-12-28 | 2009-07-09 | Biolnvent International Ab | Formulation |
ES2406029T3 (es) | 2008-04-15 | 2013-06-05 | Grifols Therapeutics Inc. | Ultrafiltración/diafiltración en dos fases |
AU2010221156A1 (en) * | 2009-03-06 | 2011-09-22 | Genentech, Inc. | Antibody formulation |
US9586180B2 (en) * | 2009-03-24 | 2017-03-07 | Wyeth Llc | Membrane evaporation for generating highly concentrated protein therapeutics |
JP2012526121A (ja) * | 2009-05-04 | 2012-10-25 | アボツト・バイオテクノロジー・リミテツド | ヒト抗tnfアルファ抗体の安定した高蛋白質濃度製剤 |
KR101912169B1 (ko) | 2010-02-04 | 2018-10-26 | 체에스엘 베링 아게 | 면역글로불린 제제 |
EP2361636A1 (de) | 2010-02-26 | 2011-08-31 | CSL Behring AG | Immunglobulinpräparat und Aufbewahrungssystem für ein Immunglobulinpräparat |
CA2976671C (en) | 2010-03-01 | 2021-01-12 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
CN103282042B (zh) | 2010-09-17 | 2014-12-10 | 巴克斯特国际公司 | 通过具有组氨酸的水性制剂在弱酸性至中性pH稳定的免疫球蛋白 |
TWI606840B (zh) | 2010-11-11 | 2017-12-01 | 艾伯維生物技術有限責任公司 | 具有增進高濃度之抗-TNFα抗體之液體調配物 |
AU2012250924B2 (en) | 2011-05-02 | 2017-05-25 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
WO2013023362A1 (zh) * | 2011-08-16 | 2013-02-21 | 深圳市卫武光明生物制品有限公司 | 静注巨细胞病毒人免疫球蛋白及其制备方法 |
MY165164A (en) | 2011-08-26 | 2018-02-28 | Baxalta Inc | Method for reducing the thromboembolic potential of a plasma-derived immunoglobulin composition |
WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
JP6463268B2 (ja) | 2012-09-07 | 2019-01-30 | コヒラス・バイオサイエンシズ・インコーポレイテッド | 安定水性アダリムマブ製剤 |
EP2727602A1 (de) * | 2012-10-31 | 2014-05-07 | Takeda GmbH | Verfahren zur Herstellung einer hochkonzentrierten Flüssigkeitsformulierung eines Antikörpers |
EP2727643A1 (de) | 2012-10-31 | 2014-05-07 | Takeda GmbH | Ultrafiltrierung von pharmazeutischen Zusammensetzungen |
CA2923859C (en) | 2013-09-11 | 2021-11-23 | Arsia Therapeutics, Inc. | Liquid protein formulations containing viscosity-lowering agents |
JP2014062100A (ja) * | 2013-11-05 | 2014-04-10 | Glaxosmithkline Llc | 抗体処方 |
EA201692002A1 (ru) * | 2014-04-07 | 2017-01-30 | Сиэтл Дженетикс, Инк. | Стабильные составы для антител к cd19 и конъюгатов антитело-лекарственное средство |
US10400019B2 (en) * | 2014-05-01 | 2019-09-03 | Virginia Tech Intellectual Properties, Inc. | Keratin nanomaterials and methods of production |
SG10201902915VA (en) | 2014-10-01 | 2019-04-29 | Eagle Biologics Inc | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
EP3334747B1 (de) | 2015-08-13 | 2023-09-27 | Amgen Inc. | Geladene tiefenfiltration von antigenbindenden proteinen |
US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
US11071782B2 (en) | 2016-04-20 | 2021-07-27 | Coherus Biosciences, Inc. | Method of filling a container with no headspace |
EA201990998A1 (ru) | 2016-10-21 | 2019-11-29 | Фармацевтические составы и способы их получения | |
EP3606964A4 (de) | 2017-04-03 | 2020-12-09 | Immunomedics, Inc. | Subkutane verabreichung von antikörper-arzneimittelkonjugaten zur krebstherapie |
EP3624846A1 (de) | 2017-05-16 | 2020-03-25 | Bhami's Research Laboratory, Pvt. Ltd. | Hochkonzentrierte proteinformulierungen mit reduzierter viskosität |
US20210171573A1 (en) * | 2018-08-14 | 2021-06-10 | Bristol-Myers Squibb Company | Improved protein recovery |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3272680D1 (en) | 1981-05-01 | 1986-09-25 | Miles Lab | Oral pharmaceutical composition containing immune globulin |
JPH01268646A (ja) * | 1988-04-20 | 1989-10-26 | Meiji Milk Prod Co Ltd | 抗腫瘍剤 |
US5766947A (en) * | 1988-12-14 | 1998-06-16 | Astra Ab | Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor |
CH684164A5 (de) | 1992-01-10 | 1994-07-29 | Rotkreuzstiftung Zentrallab | Intravenös anwendbare Immunglobulinlösung. |
DE4211169C1 (de) * | 1992-03-31 | 1993-06-03 | Klaus Kretzschmar | |
WO1993023556A1 (en) * | 1992-05-08 | 1993-11-25 | Genentech, Inc. | Antibodies to leukemia inhibitory factor |
JPH08508240A (ja) | 1993-01-12 | 1996-09-03 | ジョージ グリスティーナ,アンソニー | 受動免疫の直接的濃厚伝達のための方法および組成物 |
DE4344824C1 (de) * | 1993-12-28 | 1995-08-31 | Immuno Ag | Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung |
CN102416176A (zh) * | 1995-07-27 | 2012-04-18 | 基因技术股份有限公司 | 稳定等渗的冻干蛋白质制剂 |
-
1996
- 1996-05-24 GB GBGB9610992.1A patent/GB9610992D0/en active Pending
-
1997
- 1997-05-21 AR ARP970102171A patent/AR007249A1/es not_active Application Discontinuation
- 1997-05-22 ES ES97923962T patent/ES2258277T3/es not_active Expired - Lifetime
- 1997-05-22 CN CN97194891A patent/CN1219882A/zh active Pending
- 1997-05-22 WO PCT/EP1997/002595 patent/WO1997045140A1/en active IP Right Grant
- 1997-05-22 YU YU53098A patent/YU53098A/sh unknown
- 1997-05-22 CA CA002254983A patent/CA2254983A1/en not_active Abandoned
- 1997-05-22 AT AT97923962T patent/ATE318146T1/de not_active IP Right Cessation
- 1997-05-22 PL PL97330111A patent/PL330111A1/xx unknown
- 1997-05-22 KR KR1019980709489A patent/KR20000015935A/ko not_active Application Discontinuation
- 1997-05-22 US US09/180,485 patent/US6252055B1/en not_active Expired - Lifetime
- 1997-05-22 AP APAP/P/1998/001392A patent/AP9801392A0/en unknown
- 1997-05-22 EA EA199800946A patent/EA001860B1/ru not_active IP Right Cessation
- 1997-05-22 DE DE69735295T patent/DE69735295T2/de not_active Expired - Lifetime
- 1997-05-22 ZA ZA974486A patent/ZA974486B/xx unknown
- 1997-05-22 CZ CZ983824A patent/CZ382498A3/cs unknown
- 1997-05-22 JP JP54155397A patent/JP3338060B2/ja not_active Expired - Fee Related
- 1997-05-22 NZ NZ332625A patent/NZ332625A/xx unknown
- 1997-05-22 TR TR1998/02423T patent/TR199802423T2/xx unknown
- 1997-05-22 AU AU29589/97A patent/AU731950B2/en not_active Ceased
- 1997-05-22 BR BR9709267A patent/BR9709267A/pt not_active IP Right Cessation
- 1997-05-22 IL IL12694097A patent/IL126940A0/xx unknown
- 1997-05-22 CO CO97028095A patent/CO4850562A1/es unknown
- 1997-05-22 EP EP97923962A patent/EP0907378B1/de not_active Revoked
- 1997-05-23 PE PE1997000415A patent/PE69098A1/es not_active Application Discontinuation
- 1997-05-23 ID IDP971722A patent/ID16966A/id unknown
-
1998
- 1998-11-10 IS IS4892A patent/IS4892A/is unknown
- 1998-11-23 NO NO985464A patent/NO985464L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EA001860B1 (ru) | 2001-10-22 |
ES2258277T3 (es) | 2006-08-16 |
YU53098A (sh) | 2000-03-21 |
KR20000015935A (ko) | 2000-03-15 |
BR9709267A (pt) | 1999-08-10 |
PE69098A1 (es) | 1998-12-02 |
CO4850562A1 (es) | 1999-10-26 |
TR199802423T2 (xx) | 1999-02-22 |
EP0907378A1 (de) | 1999-04-14 |
ZA974486B (en) | 1998-11-23 |
IS4892A (is) | 1998-11-10 |
IL126940A0 (en) | 1999-09-22 |
DE69735295D1 (de) | 2006-04-27 |
DE69735295T2 (de) | 2006-10-05 |
AU731950B2 (en) | 2001-04-05 |
WO1997045140A1 (en) | 1997-12-04 |
AU2958997A (en) | 1998-01-05 |
AP9801392A0 (en) | 1998-12-31 |
CZ382498A3 (cs) | 1999-05-12 |
PL330111A1 (en) | 1999-04-26 |
GB9610992D0 (en) | 1996-07-31 |
JPH11512753A (ja) | 1999-11-02 |
CA2254983A1 (en) | 1997-12-04 |
AR007249A1 (es) | 1999-10-27 |
NO985464L (no) | 1999-01-18 |
NZ332625A (en) | 2000-04-28 |
JP3338060B2 (ja) | 2002-10-28 |
US6252055B1 (en) | 2001-06-26 |
CN1219882A (zh) | 1999-06-16 |
ID16966A (id) | 1997-11-27 |
EA199800946A1 (ru) | 1999-06-24 |
NO985464D0 (no) | 1998-11-23 |
EP0907378B1 (de) | 2006-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE318146T1 (de) | Verfahren zur aufkonzentrierung von antikörperlösungen | |
DE69824845D1 (de) | Verfahren zur aufkonzentration von kohlenwasserstoffen | |
DE69709061D1 (de) | Verfahren zur umsetzung von ethylbenzol | |
DE69603255D1 (de) | Verfahren zur modifizierung von oberflächen | |
DE69910557D1 (de) | Verfahren zur reinigung von aminonitrilen | |
DE69812693D1 (de) | Verfahren zur oligomerisierung von isobuten | |
DE69535022D1 (de) | Verfahren zur verbesserung von destillat | |
DE69507617D1 (de) | Verfahren zur stabilisierung von aufschlämmungen | |
DE69624729D1 (de) | Verfahren zur selektiven öffnung von naphtalinringen | |
DE69725000D1 (de) | Verfahren zur druckformung von gegenständen | |
DE69518550D1 (de) | Verfahren zur bereitung von kohlenwasserstoffe | |
DE69727395D1 (de) | Verfahren zur olefinisomerisierung | |
DE69715424D1 (de) | Verfahren zur halogenierung von isoolefin-para-alkylstyrol-copolymeren | |
DE69432859D1 (de) | Verfahren zur reinigung von kollagenase | |
DE69630686D1 (de) | Verfahren zur echtheitsprüfung von münzen | |
DE69715234D1 (de) | Verfahren zur reinigung von 1,1-difluorethan | |
DE69534886D1 (de) | Verfahren zur Isolierung von Zellkomponenten | |
DE69715884D1 (de) | Verfahren zur reinigung von lactamen | |
ATA124894A (de) | Verfahren zur direktreduktion von eisenoxidhältigem material | |
DE69723574D1 (de) | Verfahren zur detektion von mutationen | |
DE69711068D1 (de) | Verfahren zur kristallisation von losartan | |
DE69605902D1 (de) | Verfahren zur stabilisierung von schlamm | |
ATE220558T1 (de) | Verbessertes verfahren zur stabilisierung von proteinen | |
DE59706449D1 (de) | Verfahren zur aufkonzentrierung von gebrauchten schwefelsäuren | |
DE69605794D1 (de) | Verfahren zur hydrierung von iminen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |